Norgestrienone

Norgestrienone
Clinical data
Trade names	Ogyline, Planor, Miniplanor
Other names	RU-2010; A-301; 17α-Ethynyltrienolone; 17α-Ethynyltrenbolone; Δ9,11-Norethisterone; 17α-Ethynylestra-4,9,11-trien-17β-ol-3-one
Routes of; administration	By mouth
Drug class	Progestogen; Progestin; Androgen; Anabolic steroid
ATC code	G03AC07 (WHO) ;
Identifiers
	IUPAC name (8S,13S,14S,17R)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,14,15,16-octahydrocyclopenta[a]phenanthren-3-one;
CAS Number	848-21-5 ;
PubChem CID	13313;
ChemSpider	12749 ;
UNII	89386PYU9O;
KEGG	D07220 ;
CompTox Dashboard (EPA)	DTXSID30878491 ;
ECHA InfoCard	100.011.544
Chemical and physical data
Formula	C20H22O2
Molar mass	294.394 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C4\C=C3/C(=C2/C=C\[C@]1([C@@H](CC[C@]1(C#C)O)[C@@H]2CC3)C)CC4;
	InChI InChI=1S/C20H22O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,8,10,12,17-18,22H,4-7,9,11H2,2H3/t17-,18+,19+,20+/m1/s1 ; Key:GVDMJXQHPUYPHP-FYQPLNBISA-N ;
	(verify)

Norgestrienone, sold under the brand names Ogyline, Planor, and Miniplanor, is a progestin medication which has been used in birth control pills, sometimes in combination with ethinylestradiol. It was developed by Roussel Uclaf and has been registered for use only in France. Under the brand name Planor, it has been marketed in France as 2 mg norgestrienone and 50 μg ethinylestradiol tablets. It is taken by mouth.

Norgestrienone is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. It has some androgenic activity.

Norgestrienone was first described in the literature in 1965. It is sometimes referred to as a "second-generation" progestin. Norgestrienone is no longer available.